Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK To Acquire Genelabs | Contract Pharma

What are you searching for?

Sign in
Breaking News

GSK To Acquire Genelabs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline will acquire Genelabs Technologies for approximately $57 million in cash. This acquisition is part of GSK’s effort to develop new therapies for hepatitis C virus (HCV). Genelabs will become part of GSK’s Drug Discovery organization and its HCV programs will be consolidated into GSK’s therapeutic approaches already underway internally and through collaborations.
   
“Genelabs has demonstrated a strong track record in HCV drug discovery and identified numerous novel classes of inhibitors that target unprecedented mechanisms in the virus’s life cycle,” said Zhi Hong, senior vice president of the Infectious Diseases Centre for Excellence in Drug Discovery (ID CEDD) at GSK. “This arrangement, combined with our other collaborations, will give GSK a broad HCV drug discovery platform addressing novel targets and innovative therapeutic approaches.”
   
Fred Driscoll, president and chief executive officer of Genelabs, said, “This transaction provides our shareholders with certain value at a substantial premium to our stock price. Through the efforts of our experienced scientific staff and other employees, we have generated highly differentiated compounds with the potential to address unmet medical needs of people with the HCV infection. GSK’s world-class research and development organization will allow us to accelerate our strategic vision of providing novel treatments that deliver tremendous value for patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics